Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02

NCT05521022 is registered in ClinicalTrials.gov with Attralus, Inc. as lead sponsor.

NCT NCT05521022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05521022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02
Lead sponsor
Attralus, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
September 1, 2022
Completion date
March 1, 2025
Enrollment
100 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis; systemic